Skip to content
Screener

CeriBell, Inc. CBLL Return on equity

Return on equity at other companies

IAR
Integra LifeSciencesIART
-0.7%—
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-149.7%+4,074pp
iRadimed logo
iRadimedIRMD
25%+1.2pp
Teladoc Health logo
Teladoc HealthTDOC
-13%-1.0pp
iRhythm Holdings, Inc. logo
iRhythm Holdings, Inc.IRTC
-53.1%-17.4pp
ICU Medical logo
ICU MedicalICUI
-0.4%-0.2pp

Other financials

Income statement

See full
Revenue$28.1M+32.5%
Gross profit$25.9M+38.8%
Operating income-$20.0M-33.6%
Net income-$19.3M-41.2%
EPS (diluted)-$0.51-34.2%

Balance sheet

See full
Cash & equivalents$32.7M-18.6%
Total debt$21.9M+1.7%
Total equity$128.3M-25.5%
Total assets$166.3M-19.9%

Cash flow

See full
Operating cash flow-$12.9M-70.8%
CapEx$17.0K-76.1%
Free cash flow-$12.9M-69.4%

Valuation

See full
Market cap$713.7M+50.8%
Enterprise value$702.95M+54.6%
P/S7×+0.9×

Profitability

See full
Gross margin88.9%+1.1pp
Operating margin-68.6%+1.5pp
Net margin-64.7%+0.9pp
FCF margin-53.7%+4.4pp

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio9.2×-4.1×

Where this comes from

Calculated from CeriBell, Inc.’s reported figures.

net income/total stockholders equity=-43.9%

Based on trailing twelve months.

The source filing: CeriBell, Inc.’s 10-Q, filed August 10, 2026. Open the filing →

Filed
Aug 10, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342574

FAQ

What is CeriBell, Inc.'s return on equity?
CeriBell, Inc. (CBLL) reported return on equity of -43.9% in Q2 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about CeriBell, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude